News Releases

April 2, 2018
Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

– First clinical trial of a Synthetic Biotic ™ Medicine in patients – – Randomized, double-blind, placebo-controlled study evaluating safety and tolerability of SYNB1020 as primary endpoint; ammonia-lowering as secondary endpoint – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.

...
March 21, 2018
Synlogic to Present at the 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 21, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the 17 th Annual Needham Healthcare Conference at 12:15 p.m....
March 20, 2018
Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
– Strengthened balance sheet with $53.7M public offering; extended cash runway through 2019 – – Initiated Phase 1b/2a study evaluating SYNB1020 in patients with cirrhosis and hyperammonemia; topline data expected in 4Q 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 20, 2018-- Synlogic, Inc....
March 19, 2018
Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2018-- Synlogic, Inc. , (Nasdaq: SYBX ) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology (IO) program will...
March 12, 2018
Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™ Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders
– Expanded clinical data set from Phase 1 study confirms proof of mechanism and supports continued development of SYNB1020 for treatment of hyperammonemia – – A Phase 1b / 2a clinical trial to further evaluate SYNB1020 is open and screening patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar....
March 5, 2018
Synlogic to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 3:30 p.m....
February 13, 2018
Synlogic Presents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine
- Data presented at Keystone Symposium demonstrate rapid tumor rejection in preclinical models - - Data support advancement of Synthetic Biotic medicines as potential immuno-therapies for cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage...
February 8, 2018
Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., and chief financial officer, Todd Shegog will present a corporate update at the Leerink Partners 7th Annual Global Healthcare Conference at 3:00...
January 31, 2018
Synlogic Announces Underwriters’ Option Exercise in Full
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Synlogic (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced it has issued an additional 769,500 shares of common stock at the public offering price of $9.75 per...
January 24, 2018
Synlogic Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced the pricing of its underwritten public offering of 5,130,000 shares of its common stock at a public...
January 23, 2018
Synlogic Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has commenced an underwritten public offering of its common stock....
January 5, 2018
Synlogic Progresses Clinical and Preclinical Pipeline and Outlines 2018 Catalysts
– Presentation of full clinical data from first in-human study of Synthetic Biotic™ medicine expected in 1Q 2018 – – IND for SYNB1020 for the treatment of hyperammonemia in patients with liver disease has been cleared by the FDA – – Additional trials in patients with UCD and PKU expected to begin...
Displaying 73 - 84 of 115